Sore Throat After Open Neck Elective Surgery

NCT ID: NCT07124650

Last Updated: 2025-09-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

764 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-09-15

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, double-blind clinical trial aims to evaluate the effectiveness of two medications-hydrocortisone ointment and lidocaine solution-applied to the endotracheal tube in reducing postoperative throat pain, hoarseness, and cough following thyroid or parathyroid surgery with neuromonitoring.

A total of 764 adult patients undergoing elective neck surgery at Saint-Petersburg State University Hospital will be enrolled and randomly assigned to receive either a hydrocortisone-coated or lidocaine-coated endotracheal tube.

Outcomes will be assessed upon awakening from anesthesia, at 24 hours, and again at 3 days postoperatively.

The findings may contribute to improving postoperative comfort and recovery for patients undergoing similar surgical procedures.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Postoperative Sore Throat, Cough, Hoarseness Thyroid and Parathyroid Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hydrocortisone group

Participants receive endotracheal tubes coated with 1% hydrocortisone ointment to reduce postoperative sore throat and hoarseness.

Group Type EXPERIMENTAL

Hydrocortisone Acetate 1% Ointment

Intervention Type DRUG

Endotracheal tubes will be coated with 1% hydrocortisone acetate ointment prior to intubation. The ointment will be applied uniformly to the outer surface of the tube. This intervention aims to reduce postoperative throat inflammation and pain.

Lidocaine group

Participants receive endotracheal tubes coated with 0.05% lidocaine and chlorhexidine solution (Cathelgel).

Group Type EXPERIMENTAL

Lidocaine hydrochloride 0,05% with chlorhexidine

Intervention Type DRUG

Endotracheal tubes will be treated with 0.05% lidocaine hydrochloride solution combined with chlorhexidine (Cathejell). The solution will be applied to the tube surface before intubation to provide local anesthesia and reduce postoperative throat discomfort.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hydrocortisone Acetate 1% Ointment

Endotracheal tubes will be coated with 1% hydrocortisone acetate ointment prior to intubation. The ointment will be applied uniformly to the outer surface of the tube. This intervention aims to reduce postoperative throat inflammation and pain.

Intervention Type DRUG

Lidocaine hydrochloride 0,05% with chlorhexidine

Endotracheal tubes will be treated with 0.05% lidocaine hydrochloride solution combined with chlorhexidine (Cathejell). The solution will be applied to the tube surface before intubation to provide local anesthesia and reduce postoperative throat discomfort.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cathejell

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients scheduled for elective open surgery on the thyroid/parathyroid glands with intraoperative neuromonitoring.
* Age ≄18 years.
* Willing and able to provide voluntary informed consent for participation in the study.

Exclusion Criteria

* Pregnancy (for women of childbearing potential).
* Known allergy to hydrocortisone or lidocaine.
* Refusal to participate in the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Smooth Drug Development

UNKNOWN

Sponsor Role collaborator

Saint Petersburg State University, Russia

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Efremov Sergey

Deputy director for science, Saint-Petersburg state university hospital

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sergey M. Efremov, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Saint Petersburg State University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Saint Petersburg State University Hospital

Saint Petersburg, , Russia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Russia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Sergey M. Efremov, D. Med. Sc.

Role: CONTACT

+79137946090

Alexey Y. Kulikov, Ph. D. (Med.)

Role: CONTACT

+79217896909

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Sergey Efremov

Role: primary

79137946090

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SPbU-STONES-2025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.